Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced that its Director of Chemistry and Quality, Dr. Ric Zarzycki will give an invited presentation today on the Company's Cobalamin nanoparticle technology at a thought-leadership symposium being held at the American Chemical Society's 240th National Meeting + Exposition, at Boston Convention and Exhibition Center in Boston, Massachusetts, August 22-26, 2010.
MesoCoat is pleased to announce that it has acquired exclusive commercial rights to the high density infrared surface modification technology IP Portfolio from UT-Battelle, LLC. This breakthrough surface engineering technology was developed over the last decade at the infrared processing center, part of the industrial materials division of Oak Ridge National Laboratory (ORNL).
Nanocomp Technologies, Inc., a developer of energy saving performance materials and component products from carbon nanotubes (CNTs), today announced that it has been awarded a multi-million dollar Phase II contract by the United States Air Force Research Laboratory (AFRL) under the Department of Defense's Small Business Innovation Research (SBIR) program.
sp3 Diamond Technologies, Inc. (sp3), a leading supplier of diamond products, equipment and services, today introduced its newest hot-filament chemical vapor deposition (CVD) diamond reactor, the Model 665. The new dual-chamber system can accommodate up to eighteen 100 mm-diameter substrates at a time, representing a 100 percent increase in deposition area over the company's single chamber model.
The Western Hemisphere's first high-temperature (1500 degrees C) continuous production microwave furnace is now fully functional at New York's NanoMaterials Innovation Center (NMIC), a wholly owned subsidiary of Alfred Technology Resources, Inc. (ATRI).
BIND Biosciences announced today the presentation of its Medicinal Nanoengineering platform at the ACS National Meeting, including results from preclinical studies on its lead nanomedicine drug , BIND-014, scheduled to enter clinical trials later this year.
Altair Nanotechnologies, Inc. today announced the release of its Application Kit designed to give original equipment manufacturers (OEMs) the ability to apply its advanced lithium-titanate battery systems in a test environment simulating real-world operating conditions.